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To identify and characterize patients with autoantibodies against different neurofascin (NF)
isoforms.
Methods
Screening of a large cohort of patient sera for anti-NF autoantibodies by ELISA and further
characterization by cell-based assays, epitope mapping, and complement binding assays.
Results
Two different clinical phenotypes became apparent in this study: The well-known clinical
picture of subacute-onset severe sensorimotor neuropathy with tremor that is known to be
associated with IgG4 autoantibodies against the paranodal isoform NF-155 was found in 2
patients. The second phenotype with a dramatic course of disease with tetraplegia and almost
locked-in syndrome was associated with IgG3 autoantibodies against nodal and paranodal
isoforms of NF in 3 patients. The epitope against which these autoantibodies were directed in
this second phenotype was the common Ig domain found in all 3 NF isoforms. In contrast,
anti–NF-155 IgG4 were directed against the NF-155–specific Fn3Fn4 domain. The description
of a second phenotype of anti–NF-associated neuropathy is in line with some case reports of
similar patients that were published in the last year.
Conclusions
Our results indicate that anti–pan-NF-associated neuropathy differs from anti–NF-155-
associated neuropathy, and epitope and subclass play a major role in the pathogenesis and
severity of anti–NF-associated neuropathy and should be determined to correctly classify
patients, also in respect to possible differences in therapeutic response.
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The node of Ranvier has long been considered a potential site
of attack in inflammatory neuropathies. With respect to the
concept of complement-mediated reversible conduction
block induced by antiganglioside autoantibodies, the term
“paranodopathy/nodopathy” was introduced by Uncini
et al.1,2 In the past few years, non–complement-fixing IgG4
autoantibodies against paranodal proteins were described in
patients with immune neuropathies and were also comprised
under that term.3,4 Patients with autoantibodies against par-
anodal proteins present with a distinct clinical phenotype of
subacute-onset severe sensorimotor neuropathy with poor
response to intravenous immunoglobulins but excellent re-
sponse to rituximab.5–10 Autoantibodies are mostly of the
IgG4 subtype, but IgG3 and IgG2 autoantibodies have also
been described, possibly associated with early disease or
monophasic course.9,10 In these cases, complement de-
position could be demonstrated.11 Anti-neurofascin
(NF)-155 appears to be the most prevalent paranodal auto-
antibody and is strongly associated with tremor.6,12,13 NF-155
is located at the paranodes, whereas NF-186 and -140 are
nodal isoforms, the latter mainly expressed during embryonic
development.14,15 Although all 3 isoforms share the Ig domain
and some parts of the fibronectin domain,16 most autoanti-
bodies described so far were selectively directed against NF-
155.6,8 However, 2 recent studies could also detect anti-NF-
186/140 autoantibodies, mostly of the IgG4 subclass, in
patients with chronic inflammatory demyelinating poly-
radiculoneuropathy (CIDP).17,18 Single cases of patients with
autoantibodies against all isoforms and severe neuropathy
have been described.17,19 In contrast to anti–NF-155-
associated neuropathy, not much is known about neuropa-
thy with anti–pan-NF autoantibodies.
In the present study, we aimed to identify and characterize
patients with autoantibodies against NF to potentially estab-




Three different subcohorts of patients were included: sera of
182 patients with clinically suspected inflammatory neurop-
athy that were sent to our department for testing of paranodal
autoantibodies, further referred to as “comprehensive di-
agnostic testing cohort,” sera of 306 patients with a differential
diagnosis of inflammatory neuropathy who attended our de-
partment for diagnostic workup (32 finally diagnosed as
Guillain-Barré syndrome (GBS), 81 as CIDP fulfilling the
European Federation of Neurological Societies criteria,20 and
193 as noninflammatory neuropathy or suspected
inflammatory neuropathy not fulfilling the EFNS criteria;
“Würzburg cohort”), and 181 sera of a patient cohort from the
University Hospitals of Kiel and Magdeburg that were col-
lected between 2004 and 2016 (146 GBS, 21 CIDP, and 15
Miller-Fisher syndrome/Bickerstaff encephalitis; “Kiel/
Magdeburg cohort”). Diagnosis of GBS was assessed by the
Brighton criteria.21 CSF was obtained from diagnostic lumbar
puncture. The study was approved by the Ethics Committees
of the Universities of Würzburg and Kiel. Demographic data
are summarized in table 1.
Enzyme-linked immunosorbent assay
All patients were screened for anti-NF-155 autoantibodies by
ELISA, and 252 patients of the Würzburg cohort and all
anti–NF-155-positive patients were also screened for anti-
NF-186. All anti–NF-155-positive patients were tested for
anti-NF-140. CSF was available from 3 seropositive patients
and was tested at a dilution of 1:20. Five patients without
a clinical history of neuropathy who had received lumbar
puncture for other diagnostic purposes served as controls.
NF-155/-186 ELISA was performed as previously described
using the extracellular domains of human NF-155 and -186.8
For anti-NF-140 ELISA, wells were coated with recombinant
human NF-140 protein (1 μg/mL, Sino Biological Inc, Bei-
jing, China). Normal controls were run in each assay. The
normal value was set at 5 SDs above the mean of all healthy
controls that were tested in previous studies.22 Titers were
determined by measuring serial dilutions of anti–NF-positive
sera. Subclasses were detected using subclass-specific
horseradish peroxidase-conjugated secondary antibodies
(anti-IgG1: 1:1,000, anti-IgG2: 1:4,000, anti-IgG3: 1:3,000,
and anti-IgG4: 1:2,000; Invitrogen, Carlsbad, CA).
Binding assays with murine teased fibers,
sympathetic ganglia, cerebellar granular
neurons, and rat cerebellum sections
All sera were screened for paranodal and nodal autoantibodies
using binding assays with murine teased fibers as previously
described.9 The preparations were incubated with patients’
sera diluted 1:100 and 1:500 overnight at 4°C following in-
cubation with appropriate anti–human Cy3-conjugated sec-
ondary antibodies (Dianova, Hamburg, Germany, 1:100).
Cervical sympathetic ganglia were dissected from adult Lewis
rats, and 10-μm cryosections were cut. Binding assays with
patients’ and controls’ sera were performed with a dilution of
1:100 and 1:500 by incubating overnight. Cy3-conjugated
anti-human secondary antibodies were added for 2 hours. All
slides were assessed using a fluorescence microscope (Zeiss
Ax10, Zeiss, Oberkochen, Germany). Cerebellar granular
neurons were prepared from P5 mice: the cerebellum was
dissected, and cells were dissociated and suspended using
Glossary
CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; GBS = Guillain-Barré syndrome; HEK = human
embryonic kidney; MFI = mean fluorescence intensity; MFS = Miller-Fisher syndrome; NF = neurofascin.
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a papain dissociation system (Worthington Biochemical
Corporation, Lakewood, NJ). Cells were plated on cover slips
at a density of 200,000 cells per well and fixed with 4%
paraformaldehyde after 3 days, and binding assays with sera of
patients and controls were performed at a dilution of 1:500
using an anti-human Cy3-conjugated secondary antibody
(Dianova, 1:300). Anti–pan-NF served as a positive control.
Binding assays on rat cerebellum sections were performed
overnight at a serum dilution of 1:200 or CSF dilution of 1:4 on
6-μm sagittal adult rat brain cryosections optimized for de-
tection of surface antigens as has been previously described.23
Binding assays with NF-transfected human
embryonic kidney (HEK) 293 cells
Binding assays with HEK293 cells transiently transfected with
plasmids of human NF-155 and -1868 were performed as
previously described.22 Sera were used at a dilution of 1:200
and 1:500. Anti–pan-NF (1:1,000) served as a control anti-
body. Serum of 1 patient (patient 6) with immunoreactivity
against NF-155 by ELISA but no binding to NF-transfected
HEK293 cells at a dilution of 1:200 and 1:500 was additionally
tested at a dilution of 1:40. Immunostaining was assessed
using a fluorescence microscope (Zeiss Ax10).
Preabsorption experiments
Preabsorption was performed by serial incubation of patients’
sera (1:500) 1 hour each in 3 wells of a 24-well plate with NF-
155/-186–transfected HEK293 cells as described before.9 Sera
incubated in wells with contactin-1–transfected cells served as
controls. After incubation with transfected HEK293 cells, sera
were used for binding assays on teased fibers as described above.
Epitope characterization
TE671 human rhabdomyosarcoma cells stably transfected
with NF-155, NF-186, or 6 truncated forms of NF-155 and
NF-186 were previously described.8 Cells were incubated
with patients’ and controls’ sera (1:100). Detection of binding
was performed as described,8 with somemodifications: Serum
IgG binding was detected using Biotin-SP-conjugated
AffiniPure F(ab’)2 antibodies (Jackson ImmunoResearch)
and AF647-conjugated streptavidin (Jackson ImmunoR-
esearch). Mean fluorescence intensity (MFI) of the AF647
channel was calculated after gating on enhanced green fluo-
rescent protein (EGFP)high cells for NF truncations and
empty EGFP vector–transfected cells, and delta MFI was
calculated from these values. Patient 5 was only tested for
Fn3Fn4, as the sample was obtained at a later time point and
NF-155 isoform specificity had already been shown by ELISA.
Complement binding assay
ELISA plates were coated, blocked, and incubated with
patients’ sera as described above. The next day, the wells were
incubated with C1q (10 μg/mL, Sigma-Aldrich, St. Louis,
MO) for 2 hours at room temperature, following incubation
with horseradish peroxidase–conjugated anti-C1q (LifeSpan
Biosciences, Seattle, WA, 1:200) for 30 minutes. Measure-
ment of optical density was made as described above.
Data availability statement
Any data not published within the article will be shared by
request from any qualified investigator in anonymized form.
Results
Detection of anti-NF autoantibodies
Anti-NF-155 autoantibodies were detectable by ELISA in sera
of 6 patients (figure 1). Titers ranged from 1:300 to 1:6,000
(table 2). Three of the 6 anti–NF-155-positive patients were
also positively tested for anti-NF-186 and -140 (patients 1–3,
table 2). Sera of 2 patients showed an optical density slightly
above the cutoff value in the anti-NF-155 ELISA, but a second
serum sample of these patients obtained during the course of
disease was clearly negative. Of note, in none of the 252
neuropathy cases tested for anti-NF-186 independent of NF-
155 positivity, did we observe isolated anti-NF-186 positivity.
Anti-NF-155 and/or -186 autoantibodies were confirmed by
binding assays with NF-155– and NF-186–transfected
HEK293 cells in 5 of these patients (patients 1–5, figure 1).
Binding assays on murine teased fibers revealed a distinct
Table 1 Demographic data of patients of all subcohorts
Würzburg cohort (n = 306) Kiel/Magdeburg cohort (n = 181)




62 (8–84) 59 (18–87) 59 (18–84)
Sex 218 male, 88 female 91 male, 90 female 136 male, 46 female
Diagnosis
GBS 32 (22 level 1, 6 level 2, 3 level 3, and 1
level 4)
146 (75 level 1, 41 level 2, 6 level 3, and 24
level 4)
NA
CIDP 81 21 NA
Others 193 14 MFS, 1 Bickerstaff NA
Abbreviations: CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; GBS = Guillain-Barré syndrome; MFS = Miller-Fisher syndrome.
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paranodal staining in the patients with anti-NF-155 auto-
antibodies only (patients 4–6; figure 2, F–H) and a nodal
and paranodal staining in the 3 patients with anti–pan-NF
autoantibodies (patients 1–3; figure 2, A, C, and D). In
patient 1, paranodal staining was stronger than nodal
staining, and in patients 2 and 3, nodal staining was
stronger (Figure 2A, C-E). In patients 3 and 6, the fluo-
rescence signal was weaker than in the other patients, most
probably due to the low titer (Figure 2E, H). In patients 1
and 2, paranodal binding became stronger during the
course of disease (Figure 2B, D).
Preincubation assays were performed to confirm paranodal/
nodal binding as anti-NF specific. In the 2 patients who were
only positive for anti-NF-155 (patients 4 and 5), paranodal
binding was lost after preincubation with NF-155–transfected
cells, not after incubation with NF-186–transfected cells. In 2
of the patients with autoantibodies against both isoforms
(patients 1 and 2), paranodal and nodal binding were lost after
incubation with NF-155-transfected cells, but weaker para-
nodal binding persisted after incubation with NF-186–
transfected cells, suggesting the presence of at least 2 auto-
antibodies with different epitopes (supplemental figure 1,
links.lww.com/NXI/A132, and figure 3).
CSF was available from patients 2, 3, and 6. No anti-NF
autoantibodies were detectable in CSF by ELISA in patients 3
and 6. In patient 2, no anti-NF autoantibodies were detectable
in CSF by ELISA at the onset of disease (July 2014) or after 2
months (September 2014). However, 6 months after the
onset of disease, anti-NF autoantibodies were detectable,
most probably due to disruption of the blood-brain barrier
(CSF/serum albumin index 37.2 × 10−3). There was no evi-
dence of intrathecal IgG production at this time point, as no
oligoclonal bands were detectable and the CSF IgG index was
within the normal range (0.59).
Comparison of clinical phenotypes in patients
with pan-NF or NF-155–specific antibodies
All 6 anti–NF-positive patients had a clinical diagnosis of
CIDP except for patient 3 who had a monophasic course and
was classified as GBS. Yet detailed analysis of clinical pictures
showed that anti–NF-positive patients segregated into 2 dis-
tinct phenotypes.
Patients 1–3 whowere seropositive for anti-NF-155, -NF-186,
and –NF-140 had a fulminant course of disease. After GBS-
like onset, patients 1–3 quickly developed tetraplegia and
severe cranial nerve involvement. No antiganglioside
Figure 1 Binding assays with NF-155– and NF-186–transfected HEK293 cells (A-G) and ELISA (H)
Patients 1, 2, and 3 show a clear binding to NF-
155– and NF-186–transfected cells (A–C),
whereas patients 4 and 5 only bind to NF-155–
transfected and not to NF-186–transfected cells
(F and G). Healthy control serum does not bind
to the cells (E), and binding of commercial
anti–pan-NF autoantibodies to NF-155– andNF-
186–transfected cells is shown in (D). NF =
neurofascin; OD = optical density.
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Table 2 Overview of assays and clinical data of anti–NF-positive patients
Patient 1 2 3 4 5 6

























IgG3 IgG3 (course of disease:
weak IgG4)
Weak IgG3 IgG4>IgG2 IgG4 IgG3









6Ig domain > Fn3 6Ig domain >> Fn3 6Ig domain Fn3Fn4 Fn3Fn4 NA
IgG subclass (flow
cytometry)
IgG3 IgG3 Weak IgG3 IgG4 IgG4 NA

























Diagnosis CIDP CIDP GBS CIDP CIDP CIDP




<1/μL/907 mg/L 2/μL/621 mg/L <1/μL/298
mg/L

















Almost complete, locked-in Dysphagia No No No
Respiratory
insufficiency







































Mild response to IVIG
Outcome Died due to
sepsis 10 mo
after onset
Complete recovery of cranial
nerves, residual paresis of legs











Abbreviations: CIDP = chronic inflammatory demyelinating polyradiculoneuropathy; GBS = Guillain-Barré syndrome; IVIG = intravenous immunoglobulins;
NA = not available; NF = neurofascin; PE = plasma exchange.
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antibodies were detectable. Patient 3 quickly recovered within
a few months. Patients 1 and 2 needed mechanical ventilation
for several months with complete tetraplegia and were almost
locked-in. Patient 1 died due to sepsis, and patient 2 had a very
protracted course with almost 2 years in tetraplegia and still
recovering almost 5 years after onset of symptoms.
Patients 4 and 5 were young men with anti-NF-155 auto-
antibodies and presented with motor more than sensory
neuropathy associated with tremor, as described in multiple
reports.6,13 Remarkably, autonomic involvement was
a major problem in patient 4. In patient 5, action and
postural tremor and gait ataxia were the dominant symp-
toms with only minor neuropathic complaints and no au-
tonomic symptoms.
In patient 6 anti-NF-155 autoantibodies could not be con-
firmed by cell-based assay. The patient had severe sensori-
motor neuropathy without tremor.
For detailed clinical data, course of disease, and response to
treatment, see Table 2 and Supplements (supplement course
of disease, links.lww.com/NXI/A137).
Different patterns of reactivity of
autoantibodies against truncations of NF
To find out whether the autoantibodies in patients 1–3 were
directed against different epitopes or target a common epi-
tope of all NF isoforms and were thus responsible for the
positive reactivity to all 3 NF, binding assays with truncated
NF mutants were performed. Patients 1–3 showed immu-
noreactivity against the Ig domains of NF that are part of all
isoforms. In addition, patients 1 and 2 were found to be
weakly immunoreactive to Fn3, a component of the NF-155
isoform. Immunoreactivity to Fn3 as a second NF-155–
specific epitope is in line with the results of the preincubation
assays, explaining persistence of weak paranodal binding after
preincubation with NF-186–transfected HEK293 cells. Ad-
ditional immunoreactivity to Fn3 as a NF-155–specific epi-
tope also accounts for higher titers of anti-NF-155 compared
with anti-NF-186. Patients 4 and 5 were immunoreactive
against Fn3Fn4, a component of the fibronectin domain of
NF-155 that is isoform specific (figure 3).
IgG subclasses and C1q binding
ELISA with subclass-specific secondary antibodies detected
IgG4 and IgG2 as the predominant subclasses in patient 4, IgG4
in patient 5, and IgG3 in patients 1, 2, and 6. In patient 1, IgG2
was detectable at the onset of disease. No specific subclass was
detectable in patient 3, most probably due to the low titer and
lower sensitivity of the subclass-specific ELISA (figure 4). In
patient 2, a minor titer of IgG4 was transiently detectable during
the course of disease at a time when IgG3 titers peaked at
extraordinarily high titers (supplemental table, links.lww.com/
NXI/A133). Results of subclasses were confirmed by flow
cytometry. Complement deposition induced by autoantibody
bindingwas found in patients 1, 2, and 4 but not in patients 3 and
6 (both with low autoantibody titers and patient 6 without
confirmation of anti-NF-155 by cell-based assays) and patient 5
(with IgG4 only) (figure 4). In patients 1 and 2, sera of different
time points of disease with different autoantibody titers were
measured, and in total, C1q deposition correlated with IgG3
immunoreactivity (p = 0.009, r = 0.72).
Autonomic and cranial nerve involvement in
anti–NF-positive patients and binding to
the cerebellum
Autonomic involvement was present in 3 of the patients.
Patients 1 and 2 developed severe autonomic dysfunction
during intensive care treatment. Patient 1 was resuscitated
after cardiac arrest. Patient 4 had disabling orthostatic dys-
function, increased transpiration, and pollakiuria. As there is
no obvious link between NF and the autonomic nervous
Figure 2 Microphotographs of binding assays of patients’
sera to murine teased fibers
Nodal binding is marked with arrows, and paranodal binding with asterisks.
Serum of patient 1 clearly binds to the nodal and paranodal regions at the
onset of disease (A). Paranodal binding becomes more prominent during
the course of disease (B). Patient 2 binds to the nodes stronger than to the
paranodes (C and D), but paranodal binding becomes stronger during the
course of disease (D). Patient 3mainly binds to the nodal region (E), whereas
patients 4 and 5with anti-NF-155 autoantibodies bind to the paranodes only
(F andG). Patient 6weakly binds to the paranodes (H). A normal control does
not show any binding (I), and the commercial anti–pan-NF control antibody
clearly binds to the nodes and paranodes (J). Bar = 10 μm. NF = neurofascin.
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system and postganglionic autonomic fibers are un-
myelinated, binding assays with patients’ sera on sympa-
thetic cervical ganglia were performed, but we did not
detect any specific binding of patients’ sera to autonomic
neurons (data not shown). To assess binding of anti–NF-
positive sera to preganglionic B-fibers, we performed
binding assays with anterior root teased fibers of rats that
contain preganglionic sympathetic B-fibers. B-fibers are
distinguishable from A-alpha- and A-gamma-fibers by their
diameter. Binding of patients’ sera to ventral root fibers of
all diameters (supplemental figure 3, links.lww.com/NXI/
A135) and also to A-beta fibers of the dorsal root was
detected. As former studies have proposed binding of anti-
NF sera to the cerebellum as a possible correlate of
tremor,6,13 we also performed binding assays with cere-
bellum sections that showed clear binding to the molecular
and granular layer in patients 1–4 and to the molecular
layer only in patient 5 and no cerebellar binding in patient
6. Of note, strong cerebellar binding was observed in pa-
tient 2 using CSF, which was not evident in patients 3 and 6
(figure 5). Positive binding to cerebellar granular neurons
was also detectable in these patients (supplemental figure 3,
links.lww.com/NXI/A135).
Cranial nerve involvement was detectable in the 3 patients
with pan-NF autoantibodies. Patients 1 and 2 were almost
locked-in with complete facial and oculomotor palsy and
dysphagia. Patient 3 had dysphagia requiring a percutaneous
endoscopic gastrostomy tube. As concomitant glomerulone-
phritis has been described in patients with paranodal
autoantibodies,9,18,24 patients’ records were checked for renal
symptoms. There was no evidence of glomerulonephritis in
Figure 3 Epitope mapping of anti-NF autoantibodies by binding assays to truncated NF mutants and flow cytometry
TheNF isoforms consist of a common Ig6 domain and different isoform specific fibronectin domains (A, right section). Reactivity of patient sera to NF-155 and
NF-186 (A) and truncations of NF (B) by flow cytometry: patients 1, 2, and 3 show reactivity to both NF-155 (blue line) and NF-186 (orange line) compared with
control (empty RSV vector, black, filled), whereas patients 4 and 5 only react to NF-155 (A). Epitope analysis using NF truncations (B) demonstrated that
reactivity was against the 6Ig domain in 3 of the patients (patients 1–3) whowere positive for bothNF isoforms (green line). Patients 1 and 2 also reacted to the
Fn3 domain (red line). The Fn3Fn4 domain (yellow line) was recognized by the sera of patients 4 and 5, who reacted only to NF-155. Other truncated NF
variants (Fn1Fn2 = dark blue; Fn4-Mucin-Fn5 = brown; Mucin-Fn5 = purple; GFP-only control = gray filled) were not recognized by any of the sera tested (sera
1–4 and 6 tested for all mutants, serum 5 for Fn3Fn4 only). NF = neurofascin.
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patients 2–6, but patient 1 had acute-on-chronic renal failure
with mild proteinuria and hematuria since the onset of dis-
ease, so concomitant glomerulonephritis is possible, although
it was not formally diagnosed.
Discussion
In the present study, we identified 5 patients with definite
anti–NF-associated neuropathy, 3 of them presenting with
a distinct clinical phenotype of tetraplegia and cranial nerve
involvement. Our data suggest that the clinical picture is as-
sociated with the IgG subclass and epitope—IgG4 autoanti-
bodies against the Fn3Fn4 domain of NF-155 being
associated with the well-known phenotype of severe senso-
rimotor neuropathy with tremor and IgG3 autoantibodies
against the Ig domain of all isoforms leading to tetraplegia and
cranial nerve involvement.
We describe multiple clinically uniform cases of this more
severe form of anti–pan-NF-associated neuropathy, and the
distinct clinical phenotype is strengthened by identification of
a common pattern of reactivity to the 6Ig domain that is
common to all NF isoforms. The notion of anti–pan-NF-
associated neuropathy as a distinct subtype of anti-NF neu-
ropathy is supported by reports of single cases similar to our 3
patients in the last years: In a cohort by Burnor et al., 1 patient
with autoantibodies against NF-155, -186, and -140 clinically
very much resembled our patients but had IgG4 subclass
autoantibodies.17 Only recently, another patient with tetra-
plegia, respiratory failure, almost locked-in syndrome, and
IgG3 autoantibodies against NF-186/-140 and also NF-155
was reported, and ultrastructural analysis of nodal architecture
revealed occlusion of the nodal gap by myelin layers.19
In a recent study, 5 patients with anti-NF-186/-140 auto-
antibodies were compared with patients with anti-NF-155
IgG autoantibodies.18 Anti–NF-186/-140-positive patients
were found to be clinically different from anti-NF-155
patients, and 2 anti–NF-186/-140-positive patients pre-
sented with cranial nerve involvement and respiratory failure,
one of them with predominance of the IgG3 subclass.18 In
contrast to our study, patients with pan-NF antibodies of the
IgG4 subclass were also described in these studies, so possibly
the epitope appears to be themajor determinant of the clinical
picture and not the IgG subclass. However, these subclasses
may still contribute to the acuteness or other clinical aspects
of the disease. This suggests that the unique clinical picture of
our patients 1–3 may be mostly explained by the unique
epitope—a common domain of nodal NF-186/-140 and
paranodal NF-155—but may also be associated with the IgG3
Figure 4 ELISA of total IgG and IgG subclasses (bars) and C1q deposition in the complement binding assay (line)
IgG3 can be identified as the dominant subclass in patients 1, 2, and 6, IgG 2 and 4 in patient 4, and IgG4 in patient 5. Complement deposition can bemeasured
in patients 1 and 2 with IgG3 predominance and in patient 4 with IgG2 and IgG4 autoantibodies. No complement deposition was detectable in patient 5 with
predominance of IgG4 and patients 3 and 6 with low titers of total IgG. IgG = immunoglobulin G.
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subclass. In contrast to IgG4, IgG3 autoantibodies activate
complement and are considered to have a strong proin-
flammatory effect.25 Indeed, C1q binding induced by anti–pan-
NF autoantibodies could be shown in our patients by comple-
ment binding assays. Remarkably, complement deposition was
also detectable in one of the patients with the typical anti-NF-
155 IgG4 phenotype, most probably due to additional IgG2
autoantibodies that were detectable in this case. Complement
deposition may contribute to the more severe acute course of
disease in this patient compared with the other anti-NF-155 IgG
patient in our cohort. Complement-mediated conduction block
may either be reversible, as demonstrated by the case of patient 3
with GBS, or result in secondary axonal damage or nodal alter-
ations (as demonstrated in an ultrastructural case description by
Vallat et al.19) with a prolonged phase of recovery or lack of
recovery as in patients 1 and 2. Pathophysiologic studies in-
cluding passive transfer need to be conducted to further unravel
the connection between clinical phenotype and autoantibodies
in this subgroup of autoimmune neuropathy. CNS axonal
damage and deterioration of clinical severity of experimental
allergic neuritis induced by autoantibodies against the common
domain of NF-155 and NF-186 were demonstrated by injection
of pan-NF antibodies to rats indicating a pathogenic effect of
autoantibodies against the common domain of NF.8,26
Patient 6 who was anti–NF-155 positive (IgG3) by ELISA did
not present with the typical clinical phenotype of anti–NF-
155-associated neuropathy. Lack of binding in the cell-based
assay, cerebellar binding studies, and of complement
deposition and only weak nodal/paranodal binding in teased
fibers may reflect a low affinity of autoantibodies to the in vivo
conformation of NF or even a protein associated with NF in
this patient and may explain the mild phenotype.
Whereas all previous case reports of patients with pan-NF
autoantibodies only described nodal but not paranodal
binding on teased fibers,18,19 clear paranodal binding was
found in all our anti–pan-NF patients. Stronger paranodal
bindingmay be explained by additional binding to Fn3, part of
the NF-155–specific fibronectin domain, in 2 of our patients.
Remarkably, these 2 patients showed the most severe clinical
phenotype and a very long course of disease. Thus, multiple
epitopes may be a predictor of disease severity as also de-
scribed in other autoimmune diseases.27,28 The underlying
mechanism of multiple epitopes remains unclear: intra-
molecular epitope spreading could be an explanation and has
also been described in other autoimmune diseases.27 Indeed,
in patient 2, the Fn3 epitope was only detectable during the
course of disease but not at disease onset. Paranodal binding
in teased fiber assays increased respectively.
Tetraplegia was the dominant symptom in all of our patients
with anti–pan-NF autoantibodies and in single cases de-
scribed in the literature.17,29 We did not find any tremor in
these patients, but tremor may be masked by tetraplegia.
Tremor in anti-NF-155 neuropathy has been attributed to
autoantibody binding to cerebellar neurons,6 and we could
show cerebellar binding of anti-NF-155 and also anti–pan-NF
Figure 5 Binding assays with sera and CSF on rat cerebellum sections
CSF is depicted as triangular inset on the right
lower half of the panels. In contrast to a healthy
control that only shows some unspecific staining
to Purkinje cells due to tissue fixation optimized
for detection of surface antigens (A), sera of
patients 2 and 3 show distinct staining of the
granular and molecular layers (B–D). Binding of
CSF antibodies to the cerebellum can only be
shown in patient 2 and increases during the
course of disease (B and D), not in the healthy
control (A) or patient 3 (C). Bar = 100 μm. CSF =
cerebrospinal fluid; CWM = cerebral white matter;
GCL = granular cell layer; ML = molecular layer;
PCL = purkinje cell layer.
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serum. Our study is the first to detect paranodal autoantibodies
inCSF: Anti–pan-NF autoantibodies were detectable in theCSF
of patient 2 as a potential correlate of cerebellar involvement. In
comparison to the 5 patients with anti-NF-186/-140 autoanti-
bodies described by Delmont et al.,18 that also bound to the Ig
domain, the course of disease was more severe in our patients
and refractory to treatment. Lack of tremor, cranial nerve in-
volvement, and older age compared with anti-NF-155 patients
are features that were also found in the patients by Delmont
et al.18 Differences may be explained by IgG3 subclass in our
patients and mostly IgG4 in Delmont’s patients.
Remarkably, 3 of our patients including a patient with only
anti-NF-155 autoantibodies had severe autonomic in-
volvement, a feature that has not yet been investigated in
anti–NF-associated neuropathy. However, autonomic symp-
toms were also described in the single anti–pan-NF-positive
patient in the study by Burnor et al.17 As postganglionic au-
tonomic fibers are unmyelinated and we could not show any
binding to sympathetic ganglia, this can most probably be
explained by radiculitis involving preganglionic autonomic
fibers.
The role of IgG subclasses in the pathogenicity of anti-NF
autoantibodies and particularly association with therapeutic
response needs to be further studied. Detection of comple-
ment binding in our study and by others argues for
complement-mediated inflammation, which extends the
concept of anti–NF-associated neuropathy as a pure IgG4-
mediated disease. Our data indicate that testing of IgG sub-
classes should be performed when detecting autoantibodies
against paranodal proteins, and testing of anti-NF autoanti-
bodies should not be restricted to the NF-155 isoform.
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